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A B S T R A C T   
Background: The utilization of potentially inappropriate medications (PIMs) in older adults can lead to adverse 
events and increased healthcare costs. Polypharmacy, the concurrent utilization of multiple medications, is 
common in older adults with multiple chronic conditions. 
Objective: To investigate the utilization and costs of PIMs in multimorbid older adults with polypharmacy over 
time. 
Methods: This retrospective cross-sectional study used linked Medicare claims and electronic health records from 
seven hospitals/medical centers in Massachusetts (2007-2014). Participants were ≥65 years old, had ≥2 chronic 
conditions (to define multimorbidity), and used drugs from ≥5 pharmaceutical classes for ≥90 days (to define 
polypharmacy). Chronic conditions were defined using the Chronic Conditions Indicator from the Agency for 
Health Research and Quality. PIMs were defined using the American Geriatrics Society 2019 version of the Beers 
criteria. We calculated the percentage of patients with ≥1 PIMs and the percentages of patients using different 
types of PIMs. We used logistic regression analyses to test the odds of taking ≥1 PIMs. We calculated mean costs 
spent on PIMs by dividing the costs spent on PIMs by the total medication cost. 
Results: ≥69% of patients used ≥1 PIM. After adjusting for healthcare utilization, chronic conditions, medication 
intake, and demographic factors, female sex (2014: Odds ratio (OR)=1.27, 95%CI 1.25-1.30), age (2014: 
OR=0.92, 95%CI 0.90-0.93), and Hispanic ethnicity (2014: OR=1.41, 95%CI 1.27-1.56) were associated with 
PIM use. Gastrointestinal drugs and central nervous system drugs were the most commonly-used PIMs. In pa-
tients using ≥1 PIM, >10% of medication costs were spent on PIMs. 
Conclusion: The utilization of PIMs in US older adults with multimorbidity and polypharmacy is high.   
1. Introduction 
Multimorbidity, often defined as coexistence of two or more chronic 
conditions (Johnston et al., 2019), is highly prevalent in older adults 
with 55-98% of adults aged ≥65 years being multimorbid as shown by a 
systematic review (Marengoni et al., 2011). In the United States, the 
prevalence of multimorbidity has increased in the past few decades; in 
one recent study, ≥90% of adults aged ≥65 years were multimorbid 
(King et al., 2018). Due to expected increases in the aging population, 
multimorbidity is likely to become even more prevalent in the future. 
With multimorbidity often comes polypharmacy, which is commonly 
understood as the concurrent utilization of ≥5 medications (Masnoon 
et al., 2017). In the United States, as of 2011/2012, 39% of adults aged 
≥65 years used ≥5 medications (Kantor et al., 2015). 
The more medications older adults regularly use, the more likely 
they are to also use potentially inappropriate medications (PIMs) 
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(Bazargan et al., 2018, Simões et al., 2019, Roux et al., 2020). Poten-
tially inappropriate medications are defined as drugs for which the risk 
of an adverse event outweighs its clinical benefit (Fu et al., 2004). There 
are numerous judgment-based (implicit) and criterion-based (explicit) 
lists to define potentially inappropriate medications (e.g., Beers list, 
FORTA, STOPP criteria) (Motter et al., 2018, Curtin et al., 2019). The 
Beers list, published and regularly updated by the American Geriatrics 
Society (AGS) (American Geriatrics Society, 2015, American Geriatrics 
Society, 2019, American Geriatrics Society, 2012), are commonly-used 
in the US. 
The utilization of potentially inappropriate medications in older 
adults can be problematic because it may lead to health problems, such 
as adverse drug reactions, falls, cognitive decline, and functional 
impairment (Xing et al., 2019, Masumoto et al., 2018, Koyama et al., 
2014, Liew et al., 2019, Fabbietti et al., 2018). This in turn results in 
greater health service use, in particular hospitalizations and emergency 
department visits, thus contributing to higher health care costs (Hytti-
nen et al., 2016, Heider et al., 2018, Lau et al., 2005, Weeda et al., 2020). 
For now however, the evidence on the association between the use of 
potentially inappropriate medications and mortality is mixed (Paque 
et al., 2019, do Nascimento et al., 2017, Huang et al., 2019). 
Previous research efforts have largely focused on the utilization of 
potentially inappropriate medications in older adults more broadly, in 
patients with specific diseases or in specific settings (e.g. aged ≥65 
years, community dwelling vs. older adults in nursing homes, hospital-
ized older adults, patients with Alzheimer’s disease) (Xing et al., 2019, 
Hyttinen et al., 2016, Cho et al., 2019, Fralick et al., 2020, Tao et al., 
2020). Conversely, little is known about the use of potentially inap-
propriate medications in multimorbid older adults with polypharmacy 
issues, even though this population may be at even greater risk of 
adverse health outcomes. Therefore, the goal of this study was to 
investigate the utilization of and spending on potentially inappropriate 
medications in older multimorbid men and women with polypharmacy 
in the US from 2007 to 2014. Exploring these factors could inform in-
terventions and policy discussions on how to optimize pharmacotherapy 
in this population group. 
2. Methods 
2.1. Data Source 
To perform this retrospective cross-sectional study, we used a linked 
dataset of patients who were enrolled in the Partners Research Patient 
Data Registry (RPDR) (Partners Healthcare, 2020) and were benefi-
ciaries of Centers for Medicare and Medicaid Services (CMS), which 
means that administrative claims for these patients were available in the 
CMS database. The linked dataset contains data from 569,969 partici-
pants from January 1, 2007 through December 31, 2014. The RPDR 
contains electronic health records from two tertiary medical centers, 
three community hospitals, a rehabilitation center, and a psychiatric 
hospital in the Boston metropolitan area. Records include de-
mographics, inpatient and outpatient encounters, labs and results, pre-
scribing and dispensing records, and other medical care. The Medicare 
claims are from Parts A (inpatient coverage), B (outpatient coverage), 
and D (drug coverage). These data include information about drugs 
dispensed, medical diagnoses, and start/end dates of insurance coverage 
(Desai et al., 2018). The use of pharmacy claims is considered the gold 
standard for measuring medication utilization (West et al., 1994, West 
et al., 1995). Therefore, the use of linked data allowed for the complete 
capture of clinical criteria to define potentially inappropriate medica-
tions (e.g., creatinine) and medication utilization by patients. 
2.2. Patient Population 
2.2.1. Multimorbidity 
Chronic conditions were defined using the Chronic Condition 
Indicator (CCI) of the Agency for Healthcare Research and Quality 
(AHRQ), which categorizes ICD-9 diagnosis codes as chronic and not 
chronic (HCUP Chronic Condition Indicator (CCI) 2009). First, we 
extracted the ICD-9 codes classified as chronic. Then we assigned related 
codes (e.g. 249.0 secondary diabetes mellitus, 249.1 secondary diabetes 
mellitus with ketoacidosis, 250.0 diabetes mellitus) to ICD-9 code cat-
egories to ensure that people with two closely-related diagnoses were 
not misclassified as having multiple chronic conditions. We excluded 
chronic conditions from the CCI related to pregnancy and childbirth due 
to their non-relevance in our study population. We ended up with 77 
categories of chronic conditions (eTable1 in the supplementary mate-
rials). This approach allowed us to capture patients with different and 
more types of chronic conditions, compared to commonly-used lists of 
comorbidities, such as the Elixhauser comorbidity tool with 30 cate-
gories (Elixhauser et al., 1998). We required ≥2 diagnosis codes on 
separate days for the category to count as a chronic condition to increase 
the specificity of the underlying condition (Franklin et al., 2019). We 
considered patients as multimorbid when they had diagnoses from two 
or more categories, since this cut-off is widely used in the literature 
(Johnston et al., 2019, Smith et al., 2016, Barnett et al., 2012). 
2.4. Polypharmacy 
To define polypharmacy, we used information provided by the U.S. 
Food and Drug Administration on the classification of medications 
available on the US market into different pharmaceutical classes (e.g., 
HMG-CoA reductase inhibitors/statins) (U.S. Food and Drug Adminis-
tration, 2019). Because molecularly-related medications are typically 
considered interchangeable (e.g., within statins), we measured utiliza-
tion at the class level (eAppendix1 in the supplementary materials). We 
defined all pharmaceutical classes with ≥90 days’ supply as chronic use 
(Lauffenburger et al., 2018). To define polypharmacy, days’ supply from 
claims was defined conservatively. First, for fills on the same day, we 
assumed concurrent utilization and if the recorded durations differed, 
we selected the medication with the longest supply. Second, for 
non-concurrent fills, we used a limited shift of supply (30 days) for 
overlapping utilization. We considered patients as receiving poly-
pharmacy when they had ≥5 pharmaceutical classes with ≥90 days’ 
supply each. This ≥5 medication threshold is commonly used in the 
literature (Masnoon et al., 2017). 
2.5. Inclusion and Exclusion Criteria 
Patients were excluded if they did not have any claim (medication, 
procedure or encounter) from 2007 to 2014 (13,726, 2.4% of total). 
Second, we restricted the study population to individuals who are ≥65 
years of age. Third, we excluded patients if there was missing informa-
tion on their sex (0.5-3.7% depending on the year). Fourth, we excluded 
patients if they were enrolled in Medicare for <180 days in the year of 
the respective analysis. Next, we excluded patients without ≥5 medi-
cation classes with ≥90 days’ supply each (i.e., long-term use). And 
finally, we excluded patients who did not have chronic conditions from 
≥2 categories as defined above. A cohort flow diagram for each year 
from 2007 to 2014 can be found in the supplementary materials (eFig-
ure 1). 
3. Potentially Inappropriate Medication Use 
We identified potentially inappropriate medications using the 
American Geriatrics Society (AGS) 2019 updated version of the Beers 
criteria for potentially inappropriate medications use in older adults 
(American Geriatrics Society, 2019). The Beers criteria contain 
evidence-based recommendations that are formulated through a 
consensus panel of experts using the Delphi method (American Geriat-
rics Society, 2019). We chose to use the 2019 Beers list, rather than 
previous versions, to inform current clinical decision-making. All 
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medications dispensed that met any of the drug, dosage, and duration 
requirements specified in table 2 of the 2019 Beers criteria were iden-
tified as potentially inappropriate. Some of the drugs listed in the 2019 
Beers criteria are considered as potentially inappropriate only when 
they are used for more than a certain number of days, together with or 
without a certain diagnosis, or when certain laboratory values are below 
a certain level (e.g. creatinine clearance <30mL/min and use of nitro-
furantoin). For example, non-cyclooxygenase-selective nonsteroidal 
anti-inflammatory drugs (NSAIDs) are considered potentially inappro-
priate when used chronically, which we defined as ≥90 days when no 
other information was provided (Lauffenburger et al., 2018). We chose 
to focus on dispensed medications and utilization to confirm that pa-
tients actually filled the medications as opposed to just being prescribed 
them. 
3.1. Statistical Analyses 
The cohorts were created using the Aetion Evidence Platform 
(Version: r3.5.20180426_1659), which has previously been validated for 
a range of studies. (Aetion Evidence Platform®, 2020, Wang et al., 2016) 
Descriptive analyses were performed with STATA 15.1 (StataCorp, 
College Station, TX, USA). 
We described the demographics and main clinical characteristics of 
the study participants. We presented a selection of chronic conditions 
using the Coding Algorithms for Elixhauser Comorbidities by Quan et al. 
(Quan et al., 2005). We calculated the percentage of patients with ≥1 
potentially inappropriate medication in different age groups and in 
subgroups with different levels of chronic conditions and long-term 
medication use. We used logistic regression analyses, including multi-
variable analyses adjusting for measurable covariates (age-continuous, 
sex-binary, Hispanic ethnicity-categorical, race-categorical, number of 
chronic conditions-continuous, number of medications 
dispensed-continuous, number of hospital admissions-continuous, 
number of emergency department visits-continuous, number of ambu-
latory visits-continuous, types of comorbidities-categorical), to test the 
odds of taking ≥1 PIM. We calculated the percentages of men and 
women using different types of potentially inappropriate medications 
from 2007 to 2014. We counted the number of unique potentially 
inappropriate medications in different age groups as well as in sub-
groups of patients with different levels of chronic conditions and 
medication utilization. Finally, to capture additional consequences of 
potentially inappropriate medication utilization, we calculated mean 
costs spent on PIMs by dividing the costs spent on PIMs by the total 
medication costs (based on allowed amounts covered by Medicare). We 
also performed analyses with different thresholds of chronic conditions 
(<2) and long-term medications (<5, ≥10). 
3.2. Ethical approval 
This study was approved by the Brigham and Women’s Hospital 
Institutional Review Board. 
3.3. Additional information 
This research follows the requirements of the ‘Strengthening the 
Reporting of Observational Studies in Epidemiology’ (STROBE) report-
ing guideline (von Elm et al., 2008). 
4. Results 
Of all 569,969 patients in the RPDR-CMS database, between 61,500 
and 103,153 met criteria and were defined as multimorbid with poly-
pharmacy for the yearly cross-sectional analyses from 2007 to 2014 
(eFigure 1). Their demographics and main clinical characteristics are 
described in Table 1. The average age (range: 77.3-77.8 years), BMI 
(range: 28.7-29.1), number of long-term medications (mean: 7.2), and 
distributions by race/ethnicity stayed fairly similar over time. More 
differences between years were noted for female sex (decrease from 
65.2% in 2007 to 59.3% in 2014), mean number of chronic conditions 
(increase from 7.2 to 8.4) and certain chronic conditions. 
As shown in Table 2, ≥69% of multimorbid older men and women 
with polypharmacy across all ages used ≥1 potentially inappropriate 
medication from 2007 to 2014. In addition to differences by sex, there 
also appeared to be age differences. When we excluded PIM recom-
mendations that had a low quality of evidence (as defined by the AGS 
Beers criteria themselves), the percentage of patients with ≥1 PIM 
dropped slightly but remained above 63% in both men and women. The 
same age and sex differences were observed (eTable2 in the supple-
mentary materials). 
Table 3 presents the associations of different sociodemographic and 
other variables (e.g. health services use, medication count, and chronic 
conditions count) with the utilization of potentially inappropriate 
medications in the 2007 and 2014 cohort (first and last year of available 
data). In both 2007 and 2014, female sex (2007: Odds ratio (OR)=1.14, 
95%CI 1.11-1.16; 2014: OR=1.27, 95%CI 1.25-1.30), age (2007: 
OR=0.94, 95%CI 0.92-0.95; 2014: OR=0.92, 95%CI 0.90-0.93), and 
Hispanic ethnicity (2007: OR=1.19, 95% CI 1.04-1.36; 2014: OR=1.41, 
95% CI 1.27-1.56) were associated with the utilization of potentially 
inappropriate medications. While significant in 2007, most categories of 
the race variable were no longer statistically significant in 2014. 
Central nervous system (e.g. benzodiazepines, antidepressants, an-
tipsychotics, etc.) and gastrointestinal potentially inappropriate medi-
cations (e.g., proton-pump inhibitors) were the most common 
potentially inappropriate medications in both sexes (Figure 1 and 
eFigure 2). As shown by eFigure 2 in the supplementary materials, we 
observed sex differences in commonly used types of potentially inap-
propriate medications. Cardiovascular potentially inappropriate medi-
cations were more common in men than in women, while their 
utilization along with endocrine potentially inappropriate medications 
decreased in both sexes over time. Potentially inappropriate anticho-
linergic medications and pain medications were used in around 10% of 
patients, with slightly lower use in men than in women. 
The number of potentially inappropriate medications per patient 
remained stable over time (median: 1, IQR: 1-2, eTable3). The average 
number of PIMs and the percentage of patients with ≥1 potentially 
inappropriate medication increased as the number of pharmaceutical 
classes increased, in patients with and without multimorbidity (eTable4 
and eTable5). 
As shown in Table 4, in older multimorbid patients with poly-
pharmacy using ≥1 PIM, between 11.0% and 12.8% of medication costs 
were spent on potentially inappropriate medications in women and 
between 11.0% and 12.2% in men throughout the study period. The 
average amount spent on PIMs ranged from $392 USD to $719 for 
women and $395 to $759 for men from 2007 to 2014. 
5. Discussion 
In this study of US older adults with multiple chronic conditions and 
polypharmacy medication use, ≥69% in this population use ≥1 PIM, 
with differences that did not change over time. Meaningful gaps by sex 
were also observed, as women had a higher likelihood of using poten-
tially inappropriate medications than men. Central nervous system and 
gastrointestinal medications were the most common PIMs in both men 
and women. The impact of PIM use is substantial, as >10% of all 
medication expenses by Medicare were spent on potentially inappro-
priate medications in patients using ≥1 PIM. 
To our knowledge, this is the first study to specifically focus on the 
utilization of potentially inappropriate medications in older multi-
morbid adults with polypharmacy. Most previous research has investi-
gated the utilization of potentially inappropriate medications in broader 
groups of older adults, even though they may be at lower risk of com-
plications from PIM use. A recent meta-analysis of 66 studies from 27 




Demographics and main clinical characteristics of adults aged ≥65 years with multimorbidity* and polypharmacy**, by year   
2007 2008 2009 2010 2011 2012 2013 2014  
n = 61,500 n = 67,816 n = 72,394 n = 75,567 n = 82,030 n = 88,114 n = 102,547 n = 103,153 
Mean age (SD), years 77.3 (7.4) 77.5 (7.5) 77.6 (7.6) 77.7 (7.7) 77.7 (7.7) 77.8 (7.7) 77.8 (7.8) 77.8 (7.7) 
Female sex (%) 40,088 (65.2) 43,390 (64.0) 45,909 (63.4) 47,405 (62.7) 50,344 (61.4) 53,311 (60.5) 61,408 (59.9) 61,143 (59.3) 
Hispanic ethnicity (%) 1,161 (1.9) 1,288 (1.9) 1,431 (2.0) 1,519 (2.0) 1,616 (2.0) 1,684 (1.9) 1,688 (1.7) 1,656 (1.6) 
Race*         
White (%) 55,207 (89.8) 60,897 (89.8) 64,851 (89.6) 67,596 (89.5) 73,395 (89.5) 78,845 (89.5) 92,525 (90.2) 92,891 (90.1) 
African-American (%) 2,921 (4.8) 3,223 (4.8) 3,413 (4.7) 3,540 (4.7) 3,848 (4.7) 4,086 (4.6) 4,430 (4.3) 4,408 (4.3) 
Asian (%) 966 (1.6) 1,047 (1.5) 1,094 (1.5) 1,128 (1.5) 1,169 (1.4) 1,188 (1.4) 1,149 (1.1) 1,123 (1.1) 
Native American / Native Hawaiian (%) ◦◦ ◦◦ 53 (0.1) 45 (0.1) 48 (0.1) 45 (0.1) 47 (0.1) 49 (0.1) 
Other (%) 2,278 (3.7) 2,515 (3.7) 2,847 (3.9) 3,065 (4.1) 3,285 (4.0) 3,526 (4.0) 3,724 (3.6) 3,765 (3.7) 
Missing information (%) ◦◦ ◦◦ 130 (0.2) 194 (0.3) 270 (0.33) 400 (0.5) 643 (0.6) 886 (0.9) 
Mean BMI (SD) 28.9 (6.1) 28.7 (6.1) 28.9 (6.2) 29.1 (6.3) 29.1 (6.2) 28.9 (6.2) 28.8 (6.1) 28.9 (6.1) 
Number of chronic conditions         
Median (IQR) 7 (4) 7 (4) 7 (4) 7 (5) 7 (4) 8 (4) 8 (4) 8 (4) 
Mean (SD) 7.2 (3.0) 7.4 (3.2) 7.5 (3.2) 7.7 (3.3) 8.0 (3.5) 8.1 (3.5) 8.2 (3.6) 8.4 (3.6) 
Number of drugs dispensed*         
Median (IQR) 11 (6) 11 (6) 11 (6) 11 (6) 11 (6) 11 (6) 12 (6) 12 (6) 
Mean (SD) 11.8 (4.7) 12.0 (4.8) 12.1 (4.8) 12.1 (4.8) 12.3 (4.9) 12.2 (4.9) 12.5 (5.0) 12.5 (5.0) 
Number of drugs per patient with ≥90-day supply         
Median (IQR) 7 (3) 7 (3) 7 (3) 7 (3) 7 (3) 7 (3) 7 (3) 7 (3) 
Mean (SD) 7.2 (2.2) 7.1 (2.2) 7.2 (2.2) 7.2 (2.2) 7.2 (2.2) 7.2 (2.2) 7.3 (2.3) 7.2 (2.3) 
Healthcare utilization         
≥1 hospital admission (%) 20,515 (33.4) 24,863 (36.7) 27,137 (37.5) 28,451 (38.7) 30,537 (37.2) 31,541 (35.8) 35,227 (34.4) 34,999 (34) 
≥1 ER visit (%) 29,316 (47.7) 32,898 (48.5) 34,713 (48.0) 36,804 (48.7) 40,269 (49.1) 43,591 (49.5) 50,251 (49.0) 50,255 (48.7) 
≥1 ambulatory visit (%) 61,159 (99.4) 66,487 (98.0) 70,413 (97.3) 73,317 (97.0) 79,694 (97.2) 85,820 (97.4) 99,920 (97.4) 100,543 (97.5) 
Comorbidities***         
Congestive heart failure (%) 12,673 (20.6) 14,613 (21.6) 15,534 (21.5) 16,366 (21.7) 18,402 (22.4) 19,920 (22.6) 23,145 (22.6) 23,793 (23.1) 
Cardiac arrhythmias (%) 6,460 (10.5) 7,355 (10.9) 7,483 (10.3) 8,001 (10.6) 8,932 (10.9) 9,550 (10.8) 10,526 (10.3) 10,936 (10.6) 
Valvular disease (%) 10,172 (16.5) 11,073 (16.3) 11,689 (16.2) 12,257 (16.2) 14,221 (17.3) 15,439 (17.5) 18,456 (18.0) 19,204 (18.6) 
Pulmonary circulation disorders (%) 2,000 (3.3) 2,570 (3.8) 2,900 (4.0) 3,273 (4.3) 4,074 (5.0) 4,559 (5.2) 5,381 (5.3) 5,799 (5.6) 
Peripheral vascular disorders (%) 12,601 (20.5) 14,462 (21.3) 15,291 (21.1) 15,828 (21.0) 17,639 (21.5) 19,019 (21.6) 21,684 (21.2) 21,907 (21.2) 
Hypertension (%) 49,089 (70.1) 53,845 (79.4) 57,979 (80.1) 60,931 (80.6) 67,096 (81.8) 72,000 (81.7) 84,011 (81.9) 83,992 (81.4) 
Other neurological disorders (%) 4,593 (7.5) 5,307 (7.8) 5,833 (8.1) 6,512 (8.6) 7,434 (9.1) 8,380 (9.5) 9,886 (9.6) 10,266 (10.0) 
Chronic pulmonary disorders (%) 14,655 (23.8) 16,844 (24.8) 17,966 (24.8) 19,010 (25.2) 21,199 (25.8) 22,956 (26.1) 26,746 (26.1) 27,064 (26.2) 
Diabetes (%) 23,205 (37.7) 25,382 (37.4) 27,189 (37.2) 28,650 (37.9) 31,697 (38.6) 33,961 (38.5) 38,305 (38.4) 38,593 (37.4) 
Hypothyroidism (%) 12,197 (19.8) 13,783 (20.3) 14,869 (20.5) 16,068 (21.3) 18,404 (22.4) 20,290 (23.0) 24,250 (23.7) 24,892 (24.1) 
Renal failure (%) 7,090 (11.5) 8,881 (13.1) 10,257 (14.2) 11,385 (15.1) 14,052 (17.1) 16,254 (18.5) 19,873 (19.4) 21,234 (20.6) 
Liver disease (%) 2,218 (3.6) 2,510 (3.7) 2,668 (3.7) 2,879 (3.8) 3,118 (3.8) 3,448 (3.9) 4,201 (4.1) 4,480 (4.4) 
Peptic ulcer disease (excluding bleeding) (%) 521 (0.9) 653 (1.0) 658 (0.9) 726 (1.0) 878 (1.1) 970 (1.1) 1,222 (1.1) 1,071 (1.0) 
Lymphoma (%) 1,151 (1.9) 1,427 (2.1) 1,589 (2.2) 1,688 (2.2) 1,929 (2.4) 2,297 (2.6) 2,839 (2.8) 3,012 (2.9) 
Metastatic cancer (%) 1,425 (2.3) 1,925 (2.8) 2,042 (2.8) 2,305 (3.1) 2,573 (3.1) 2,941 (3.3) 3,573 (3.5) 3,566 (3.5) 
Solid tumor without metastasis (%) 9,792 (15.9) 11,213 (16.5) 11,997 (16.6) 12,745 (16.9) 14,195 (17.3) 15,601 (17.7) 18,391 (17.9) 18,862 (18.3) 
Rheumatoid arthritis/collagen vascular diseases (%) 4,344 (7.1) 4,849 (7.2) 5,212 (7.2) 5,600 (7.4) 6,341 (7.7) 7,152 (8.1) 8,528 (8.3) 8,848 (8.6) 
Coagulopathy (%) 3,059 (5.0) 3,288 (4.9) 3,556 (4.9) 3,822 (5.1) 4,249 (5.2) 4,527 (5.1) 5,331 (5.2) 5,226 (5.1) 
Weight loss (%) 2,608 (4.2) 3,264 (4.8) 3,512 (4.9) 3,962 (5.2) 4,555 (5.6) 5,007 (5.7) 6,166 (6.0) 6,201 (6.0) 
Fluid and electrolyte disorders (%) 5,045 (8.2) 5,949 (8.9) 6,477 (9.0) 6,888 (9.1) 7,644 (9.3) 8,270 (9.4) 9,422 (9.2) 9,467 (9.2) 
Psychoses (%) 2,727 (4.4) 3,301 (4.9) 3,657 (5.1) 3,984 (5.3) 4,293 (5.2) 4,624 (5.3) 5,510 (5.4) 5,571 (5.4) 
Depression (%) 19,719 (17.4) 12,542 (18.5) 13,642 (18.8) 15,060 (19.9) 17,345 (21.1) 19,494 (22.1) 23,493 (22.9) 24,275 (23.5)  
* multimorbidity defined as chronic conditions from ≥2 chronic condition categories; 
** polypharmacy defined as medications with ≥90 days’ supply each from ≥5 pharmaceutical classes 
*** comorbidities defined with coding algorithms for defining Elixhauser comorbidities in ICD-9 administrative data (Quan et al. 2005), ≥2 ICD-9 codes per category, hypertension categories merged, diabetes categories 
merged, drug abuse, alcohol abuse, obesity, HIV/AIDS, paralysis, blood loss anemia and deficiency anemia not reported;◦◦ cells with sizes 0-10 suppressed. 
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countries found that 33% of adults aged ≥65 years used ≥1 PIM, 
regardless of criteria for defining potentially inappropriate medications 
(e.g., Beers, FORTA or STOPP/START criteria) (Liew et al., 2020). 
Similarly, several studies conducted in community-dwelling adults aged 
≥65 years found that around 35-40% of them were using ≥1 PIM 
(defined by Beers criteria) (Morgan et al., 2016, Fick et al., 2008, Huang 
et al., 2020). Closer to our study population, two studies found that 
potentially inappropriate medications were used in about 50% of 
community-dwelling older adults with hypertension or diabetes 
(Bazargan et al., 2018, Gagnon et al., 2020). Contrasted with these prior 
studies, our findings suggest that PIM uses is even higher (e.g., ≥69%) in 
older adults with multiple chronic conditions and multiple long-term 
medications. 
Our findings concerning the most commonly-used potentially inap-
propriate medications are in line with prior research in this area, which 
had also identified proton-pump inhibitors, benzodiazepines and other 
central nervous system drugs, endocrine medications, such as sulfonyl-
ureas, and nonsteroidal anti-inflammatory drugs as commonly used 
potentially inappropriate medications (Bazargan et al., 2018, Simões 
et al., 2019, Roux et al., 2020, Fralick et al., 2020, Gagnon et al., 2020). 
Of note, the spike in potentially inappropriate central nervous system 
drugs in 2013 and 2014 can be explained by the fact that benzodiaze-
pines and barbiturates were covered by Medicare Part D (drug coverage) 
as of January 1, 2013 (Centers for Medicare & Medicaid Services, 2012). 
Future efforts should focus on how the prescribing of the most 
commonly-used potentially inappropriate medications could be opti-
mized and how these drugs, if applicable, could be sustainably 
deprescribed. 
We found that female sex is associated with an increased PIM use, 
which is in line with findings from studies in other settings and pop-
ulations (Simões et al., 2019, Roux et al., 2020, Gagnon et al., 2020, 
Toepfer et al., 2019, Achterhof et al., 2020). However, the mechanisms 
behind this association remain unclear. The observed sex difference 
should be interpreted with caution, since it was likely driven by more 
chronic use of certain medications in women (i.e. benzodiazepines), the 
fact that because of a lower creatinine clearance in women some 
medication may have been flagged as potentially inappropriate in 
women but not in men, or some potentially inappropriate medications 
listed in the Beers criteria are exclusively used in women (e.g. estro-
gens). It is beyond the scope of this paper to analyze the effect of sex 
differences in comorbidities or to examine potential gender biases in the 
use of potentially inappropriate medications, but future studies could 
explore this and potentially determine whether sex-based deprescribing 
interventions may be necessary. 
Our results do not suggest clinically-relevant differences by age. In 
the current literature, there is contradicting evidence on the association 
between age and the utilization of potentially inappropriate medica-
tions. Some studies found that it increases with age (Roux et al., 2020, 
Morgan et al., 2016, Gagnon et al., 2020) while another one found that 
there is no age effect (Simões et al., 2019). Despite this, the age effect 
Table 2 
Percentage of adults aged ≥65 years with multimorbidity* and polypharmacy** who filled ≥1 potentially inappropriate medication*** by year, sex, and age group   
2007 2008 2009 2010 2011 2012 2013 2014 
Both sexes (%)  
n = 61,500 n = 67,816 n = 72,394 n = 75,567 n = 82,030 n = 88,114 n = 102,547 n =103,153 
65 – 74 18,353 (75.4) 20,152 (75.9) 21,548 (75.8) 22,378 (74.7) 23,764 (73.5) 25,106 (72.3) 31,761 (78.4) 31,558 (77.6) 
75 – 84 18,991 (73.4) 20,395 (73.2) 21,235 (72.5) 21,282 (71.3) 22,622 (70.2) 23,800 (69.0) 29,458 (74.5) 28,996 (73.1) 
≥ 85 7,927 (70.3) 9,434 (70.6) 10,286 (70.1) 10,737 (68.1) 11,494 (65.8) 12,443 (65.8) 15,867 (70.5) 15,814 (69.4) 
All ages 45,271 (73.6) 49,981 (73.7) 53,069 (73.3) 54,398 (72.0) 57,880 (70.6) 61,349 (69.6) 77,086 (75.2) 76,368 (74.0) 
Women (%)  
n = 40,088 n = 43,390 n = 45,909 n = 47,405 n = 50,344 n = 53,311 n = 61,408 n = 61,143 
65 – 74 11,368 (77.3) 12,121 (77.1) 12,905 (77.1) 13,360 (76.5) 13,878 (75.3) 14,747 (74.4) 18,800 (81.6) 18,675 (81.0) 
75 – 84 12,599 (74.0) 13,205 (73.6) 13,527 (73.1) 13,405 (72.1) 13,959 (71.1) 14,317 (69.9) 17,677 (76.5) 17,314 (75.6) 
≥ 85 5,840 (69.9) 6,808 (70.1) 7,443 (69.8) 7,672 (67.7) 8,044 (65.4) 8,533 (65.6) 10,894 (71.4) 10,690 (70.5) 
All ages 29,807 (74.4) 32,134 (74.1) 33,875 (73.8) 34,437 (72.6) 35,881 (71.3) 37,597 (70.5) 47,371 (77.1) 46,679 (76.3) 
Men (%)  
n = 21,411 n = 24,425 n = 26,482 n = 28,155 n = 31,678 n = 34,793 n = 41,128 n = 42,000 
65 – 74 6,985 (72.5) 8,030 (74.1) 8,640 (73.8) 9,015 (72.2) 9,880 (71.0) 10,253 (69.5) 12,953 (74.3) 12,878 (73.1) 
75 – 84 6,392 (72.3) 7,190 (72.5) 7,708 (71.6) 7,877 (70.1) 8,662 (68.7) 9,482 (67.8) 11,780 (71.6) 11,680 (69.7) 
≥ 85 2,087 (71.2) 2,626 (71.7) 2,843 (70.9) 3,065 (69.3) 3,450 (66.8) 3,919 (66.2) 4,973 (68.7) 5,124 (67.1) 
All ages 15,464 (72.2) 17,846 (73.1) 19,191 (72.5) 19,957 (70.9) 21,992 (69.4) 23,745 (68.3) 29,706 (72.2) 29,682 (70.7)  
* multimorbidity defined as chronic conditions from ≥2 chronic condition categories 
** polypharmacy defined as medications with ≥90 days’ supply each from ≥5 pharmaceutical classes; 
*** Reference: (2019), American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr 
Soc, 67: 674-694. doi:10.1111/jgs.15767. 
Table 3 
Multivariable logistic regression analyses of the association between the use of 
potentially inappropriate medications and patient characteristics in 2007 and 
2014.   
2007 (n¼344,331) 2014 (n¼397,146)  
Multivariable model1 Multivariable model1  
Odds 
ratio 
95% CI Odds 
ratio 
95% CI 












Race (ref. White) 




Asian 1.53 1.39- 
1.68*** 
1.00 0.93-1.08 
Other2 1.39 1.27- 
1.51*** 
1.01 0.95-1.07 












Emergency room visits (1-unit 
increase) 
1.00 0.99-1.00 1.00 0.99-1.00 












1 The models are adjusted for the types of comorbidities. Comorbidities were 
defined with coding algorithms for defining Elixhauser comorbidities in ICD-9 
administrative data (Quan et al. 2005), ≥2 ICD-9 codes per category 
2 Native American, native Hawaiian and ’other’ combined. 
** p<0.05 
*** p<0.001 
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deserves to be further studied, to investigate which age group is most 
likely to benefit from deprescribing interventions. 
Further, we observed an association of the utilization of potentially 
inappropriate medications with Hispanic ethnicity, but our results 
concerning the association with race were inconclusive. This is in line 
with previous research, which found that older Hispanics were more 
likely than older Whites to use potentially inappropriate psychotropic 
medications (Lim and Jung, 2019). The question of the association be-
tween the utilization of PIMs and race and ethnicity deserves to be 
further studies, as this information may be crucial for tailoring future 
interventions to optimize medication use and deprescribe. 
The high use of potentially inappropriate medications in older adults 
is not without other consequences. A recent study from the US estimated 
that 7.3 billion doses of PIMs were dispensed in 2018 to patients who 
were enrolled in Medicare Part D and that this PIM use corresponded to a 
reported spending of US$ 4.4 billion (Fralick et al., 2020). Similarly, 
another study also conducted in the US context also found PIM use to be 
associated with higher costs (Clark et al., 2020). The fact that >10% are 
being spent potentially inappropriate medications in patients who use 
≥1 PIM means substantial additional and potentially unnecessary 
spending by Medicare. To our knowledge, this is the first study to 
investigate the cost associated with the utilization of potentially inap-
propriate medications in relation to all medication costs in the United 
States. Average yearly spending on potentially inappropriate medica-
tions in this population was higher than in a previous study conducted in 
Canada (Morgan et al., 2016), which of course could be explained by 
different drug prices in the US and Canada (Gooi and Bell, 2008, Quon 
et al., 2005, Kim et al., 2017). Further, we only measured direct costs 
associated with potentially inappropriate medications (Xing et al., 
2019), and indirect costs are likely to be much higher as higher utili-
zation of potentially inappropriate medications is associated with higher 
total medical costs (Harrison et al., 2018). 
In summary, our findings have important implications for clinical 
care and intervention development (e.g. tailored to what PIMs are most 
commonly used, based on what patient group is most likely to use PIMs). 
Due to the high utilization of potentially inappropriate medications in 
older multimorbid adults with polypharmacy and the potential negative 
and financial consequences linked to the PIM use, regular screening for 
PIMs should be incorporated in standard practice (e.g. screenings by 
pharmacists or primary care physicians) and deprescribing interventions 
should be explored. 
5.1. Limitations 
The findings of this study should be interpreted in light of several 
limitations. First, since the different tools used to define potentially 
inappropriate medications include different medications, the results of 
this study may not be comparable to studies using different tools (e.g. 
STOPP criteria instead of Beers). Different tools result in different pro-
portions of PIM use (Sakr et al., 2018, Ma et al., 2019). Second, the Beers 
criteria are criterion rather than judgment-based. Despite using di-
agnoses and clinical criteria to determine PIM use, some medications 
defined as potentially inappropriate may have been used as a last resort. 
In other cases, alternative to PIMs might have been more expensive. 
Regardless, the Beers criteria are the most commonly-used metric for 
PIM use in the US and excluding medications with a low-level of evi-
dence did not meaningfully change the results. Third, despite using a 
broad approach for identifying patients with multiple chronic condi-
tions, we cannot rule out some potential misclassification because of the 
nature of the data. Fourth, we were not able to capture dispensation 
over-the-counter medications, which may have led to an underestima-
tion of the utilization potentially inappropriate medications. Fifth, the 
data are from several years ago (owing to an administrative lag in 
acquisition and linkage); given that we observed no changes over time, 
these findings should remain relevant. Sixth, we did not account our cost 
analyses for inflation. Finally, our results might not be generalizable to 
commercially insured older adults or beyond the Boston metropolitan 
region. For example, while the demographic makeup of the metropol-
itan area compared with other urban US regions is similar (Kaiser Family 
Foundation, 2020), individuals in urban areas could have more access to 
Fig. 1. Different types of potentially inappropriate medications* used in adults aged ≥65 years with multimorbidity** and polypharmacy***, from 2007 to 2014. 
Reference: (2019), American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc, 
67: 674-694. doi:10.1111/jgs.15767– table 2. 
** multimorbidity defined as chronic conditions from ≥2 chronic condition categories; 
*** polypharmacy defines as medications with ≥90 days’ supply each from ≥5 pharmaceutical classes. 
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healthcare and physicians, which could change the prevalence of pre-
scribing of potentially inappropriate medications 
6. Conclusions 
Based on the findings of this study, we conclude that the utilization 
of potentially inappropriate medications in older multimorbid US adults 
with polypharmacy is high and has not changed over time. After 
adjusting for health services use and types of chronic conditions, female 
sex, age and Hispanic ethnicity were associated with potentially inap-
propriate medication use. The utilization of potentially inappropriate 
medications contributes to >10% of medication spending. These find-
ings demonstrate the continued need for PIM screening and depres-
cribing interventions in this population group. 
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